AstraZeneca overcame a drop in sales in China and the arrest of its top executive in the country to deliver an 18 per cent increase in revenues in the final quarter 2024.
The London-listed company said it was being investigated in China over suspected unpaid import taxes of $900,000, which could result in a fine of up to $4.5mn.
In the fourth quarter of 2024, AstraZeneca reported sales of $14.9bn, higher than the consensus forecast of $14.2bn. Core earnings per share — a key metric in the industry — were $2.09, above the average analyst forecast of $2.07.
您已阅读19%（559字），剩余81%（2314字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。